Investing Experience -
Risk Profile -
Followers
0
Following
0
Blog Posts
0
Threads
2,267
Blogs
Threads
Portfolio
Follower
Following
Summary
Total comments
2,267
Past 30 days
0
Past 7 days
0
Today
0
User Comments
Stock
2020-12-08 13:27 | Report Abuse
Hot Stock - MyEG continues to climb after emerging as potential proxy for Covid-19 vaccine play - http://www.theedgemarkets.com/article/myeg-continues-climb-after-emerging-potential-proxy-covid19-vaccine-play (Share from StockHunter)
Stock
2020-12-08 13:26 | Report Abuse
Hot Stock - MyEG continues to climb after emerging as potential proxy for Covid-19 vaccine play - http://www.theedgemarkets.com/article/myeg-continues-climb-after-emerging-potential-proxy-covid19-vaccine-play (Share from StockHunter)
Stock
2020-12-08 11:22 | Report Abuse
企业诊断/ 智飞疫苗 MYEG获大马独家分销 - https://www.sinchew.com.my/content/content_2389835.html (Share from StockHunter)
Stock
2020-12-08 11:22 | Report Abuse
企业诊断/ 智飞疫苗 MYEG获大马独家分销 - https://www.sinchew.com.my/content/content_2389835.html (Share from StockHunter)
Stock
2020-12-08 09:44 | Report Abuse
尽管目前Covid-19 流感大流行的影响带来了经济上的不确定性，MYEG还可以维持他们的业务，并且成功获得了 PLKS（Pas Lawatan Kerja Sementara）维持 3 年的合约延长期（从2020年5月23日至2023年5月22日），合约价值RM208 million !
此外MYEG 还有为 Jabatan Pengangkutan Jalan (JPJ) 提供另一项电子政府服务，以提供与车辆登记，许可证和传票付款有关的服务。MYEG也表示，与政府关于续约的谈判还没有完成，他们会继续提供服务，直到另行通知。
在2020年6月6日，公司宣布成立了一家MYEG Medical Services Sdn Bhd 的子公司，来销售医疗产品和服务。这是在5月份推出的电子政府服务提供商的网站，让雇主注册和管理员工的关于Covid19 的健康检查。同时，通过与Sosco 注册clinic小组的组合，MYEG 将安排由完全遵守卫生部指导来训练有执照的医生。
目前 MYEG 收购了S5 Holdings Inc. 的10%股权。据说，他正在和Heitech Padu 竞标合同，争取这次的大型合约。随着MYEG 成为S5 Holdings Inc. 的股东，两家公司在外籍员工数据和数字的处理方面有着丰富的经验。Billion-Ringgit 的National Integrated Immigration System (NIIS) 的项目招标工作将吸引了25加网络安全和信息的投标，中标预计将会在8月公布。MYEG 通过收购S5 Holdings Inc. 将增强该集团赢得RM1.8 billion 左右的 NIIS (National Integrated Immigration System) 的潜在机会。这是因为S5 为国家安全提供的技术系统和服务方面的专业知识已经得到了充分的证明。该公司在马来西亚，缅甸，印度，孟加拉，和尼泊尔等国家都推出了国家安全系统。MYEG 也表示， S5 是边境安全控制方面的专家，特别是为入境的旅客提供验证的系统。
在2020年6月10日， MYEG还宣布了他的子公司 MYEG Capital Sdn Bhd 已经和 Merrington Assets Ltd (MAL) 签订了Share Sale Agreement（SSA）和Put and Call Options Agreement (PCOA)协议，来购买S5 的118million 的 Ordinary Share，约RM90 million。但是，在2020年7月16日，MYEG 子公司MyEG Capital私人有限公司宣布，将脱售S5 Holdings Inc的10%股权给安康物流（Ancom Logistics Bhd）。MyEG向大马交易所报备，子公司及其他卖家，包括S7 Holdings私人有限公司、Merrington Assets Ltd与Avocat私人有限公司，已经和安康物流及其母公司安康（Ancom Bhd）签署协议，以倒置收购S5。MyEG也表示，倒置收购拿回S5的最初投资成本，S5的10%股权约RM90 million，从而使它的market cap 提高到9亿令吉。
MYEG 的第一季度报告 (FY20 1Q) 赚取了RM58.84 million 的Net Profit 也获得了 RM121.74 million 的revenue。MYEG 第一季度的利润是来自于Immigration Department 和Road Transport Department。此外，Cardbiz Group 也一起参与了支付解决方案 (payment solutions) 和硬件及商户收单服务 (hardware and merchant acquiring services) 的部署。此外，公司出色的业绩也受到了商业服务的支持 （commercial services）比如汽车交易，融资服务，税务监控系统销售，外籍工人招聘和安置的相关服务。
根据MYEG的表示，公司将继续引进创新的服务，使用该国和亚洲地区的新技术，来推动集团FY2020的增长。
#转载
Stock
2020-12-08 09:44 | Report Abuse
尽管目前Covid-19 流感大流行的影响带来了经济上的不确定性，MYEG还可以维持他们的业务，并且成功获得了 PLKS（Pas Lawatan Kerja Sementara）维持 3 年的合约延长期（从2020年5月23日至2023年5月22日），合约价值RM208 million !
此外MYEG 还有为 Jabatan Pengangkutan Jalan (JPJ) 提供另一项电子政府服务，以提供与车辆登记，许可证和传票付款有关的服务。MYEG也表示，与政府关于续约的谈判还没有完成，他们会继续提供服务，直到另行通知。
在2020年6月6日，公司宣布成立了一家MYEG Medical Services Sdn Bhd 的子公司，来销售医疗产品和服务。这是在5月份推出的电子政府服务提供商的网站，让雇主注册和管理员工的关于Covid19 的健康检查。同时，通过与Sosco 注册clinic小组的组合，MYEG 将安排由完全遵守卫生部指导来训练有执照的医生。
目前 MYEG 收购了S5 Holdings Inc. 的10%股权。据说，他正在和Heitech Padu 竞标合同，争取这次的大型合约。随着MYEG 成为S5 Holdings Inc. 的股东，两家公司在外籍员工数据和数字的处理方面有着丰富的经验。Billion-Ringgit 的National Integrated Immigration System (NIIS) 的项目招标工作将吸引了25加网络安全和信息的投标，中标预计将会在8月公布。MYEG 通过收购S5 Holdings Inc. 将增强该集团赢得RM1.8 billion 左右的 NIIS (National Integrated Immigration System) 的潜在机会。这是因为S5 为国家安全提供的技术系统和服务方面的专业知识已经得到了充分的证明。该公司在马来西亚，缅甸，印度，孟加拉，和尼泊尔等国家都推出了国家安全系统。MYEG 也表示， S5 是边境安全控制方面的专家，特别是为入境的旅客提供验证的系统。
在2020年6月10日， MYEG还宣布了他的子公司 MYEG Capital Sdn Bhd 已经和 Merrington Assets Ltd (MAL) 签订了Share Sale Agreement（SSA）和Put and Call Options Agreement (PCOA)协议，来购买S5 的118million 的 Ordinary Share，约RM90 million。但是，在2020年7月16日，MYEG 子公司MyEG Capital私人有限公司宣布，将脱售S5 Holdings Inc的10%股权给安康物流（Ancom Logistics Bhd）。MyEG向大马交易所报备，子公司及其他卖家，包括S7 Holdings私人有限公司、Merrington Assets Ltd与Avocat私人有限公司，已经和安康物流及其母公司安康（Ancom Bhd）签署协议，以倒置收购S5。MyEG也表示，倒置收购拿回S5的最初投资成本，S5的10%股权约RM90 million，从而使它的market cap 提高到9亿令吉。
MYEG 的第一季度报告 (FY20 1Q) 赚取了RM58.84 million 的Net Profit 也获得了 RM121.74 million 的revenue。MYEG 第一季度的利润是来自于Immigration Department 和Road Transport Department。此外，Cardbiz Group 也一起参与了支付解决方案 (payment solutions) 和硬件及商户收单服务 (hardware and merchant acquiring services) 的部署。此外，公司出色的业绩也受到了商业服务的支持 （commercial services）比如汽车交易，融资服务，税务监控系统销售，外籍工人招聘和安置的相关服务。
根据MYEG的表示，公司将继续引进创新的服务，使用该国和亚洲地区的新技术，来推动集团FY2020的增长。
#转载
Stock
2020-12-08 09:43 | Report Abuse
尽管目前Covid-19 流感大流行的影响带来了经济上的不确定性，MYEG还可以维持他们的业务，并且成功获得了 PLKS（Pas Lawatan Kerja Sementara）维持 3 年的合约延长期（从2020年5月23日至2023年5月22日），合约价值RM208 million !
此外MYEG 还有为 Jabatan Pengangkutan Jalan (JPJ) 提供另一项电子政府服务，以提供与车辆登记，许可证和传票付款有关的服务。MYEG也表示，与政府关于续约的谈判还没有完成，他们会继续提供服务，直到另行通知。
在2020年6月6日，公司宣布成立了一家MYEG Medical Services Sdn Bhd 的子公司，来销售医疗产品和服务。这是在5月份推出的电子政府服务提供商的网站，让雇主注册和管理员工的关于Covid19 的健康检查。同时，通过与Sosco 注册clinic小组的组合，MYEG 将安排由完全遵守卫生部指导来训练有执照的医生。
目前 MYEG 收购了S5 Holdings Inc. 的10%股权。据说，他正在和Heitech Padu 竞标合同，争取这次的大型合约。随着MYEG 成为S5 Holdings Inc. 的股东，两家公司在外籍员工数据和数字的处理方面有着丰富的经验。Billion-Ringgit 的National Integrated Immigration System (NIIS) 的项目招标工作将吸引了25加网络安全和信息的投标，中标预计将会在8月公布。MYEG 通过收购S5 Holdings Inc. 将增强该集团赢得RM1.8 billion 左右的 NIIS (National Integrated Immigration System) 的潜在机会。这是因为S5 为国家安全提供的技术系统和服务方面的专业知识已经得到了充分的证明。该公司在马来西亚，缅甸，印度，孟加拉，和尼泊尔等国家都推出了国家安全系统。MYEG 也表示， S5 是边境安全控制方面的专家，特别是为入境的旅客提供验证的系统。
在2020年6月10日， MYEG还宣布了他的子公司 MYEG Capital Sdn Bhd 已经和 Merrington Assets Ltd (MAL) 签订了Share Sale Agreement（SSA）和Put and Call Options Agreement (PCOA)协议，来购买S5 的118million 的 Ordinary Share，约RM90 million。但是，在2020年7月16日，MYEG 子公司MyEG Capital私人有限公司宣布，将脱售S5 Holdings Inc的10%股权给安康物流（Ancom Logistics Bhd）。MyEG向大马交易所报备，子公司及其他卖家，包括S7 Holdings私人有限公司、Merrington Assets Ltd与Avocat私人有限公司，已经和安康物流及其母公司安康（Ancom Bhd）签署协议，以倒置收购S5。MyEG也表示，倒置收购拿回S5的最初投资成本，S5的10%股权约RM90 million，从而使它的market cap 提高到9亿令吉。
MYEG 的第一季度报告 (FY20 1Q) 赚取了RM58.84 million 的Net Profit 也获得了 RM121.74 million 的revenue。MYEG 第一季度的利润是来自于Immigration Department 和Road Transport Department。此外，Cardbiz Group 也一起参与了支付解决方案 (payment solutions) 和硬件及商户收单服务 (hardware and merchant acquiring services) 的部署。此外，公司出色的业绩也受到了商业服务的支持 （commercial services）比如汽车交易，融资服务，税务监控系统销售，外籍工人招聘和安置的相关服务。
根据MYEG的表示，公司将继续引进创新的服务，使用该国和亚洲地区的新技术，来推动集团FY2020的增长。
#转载
Stock
Stock
2020-12-08 08:51 | Report Abuse
“The government’s deal is only with Pfizer and Covax, and does not go through any third party or middleman,” he added.
https://www.malaymail.com/news/malaysia/2020/12/07/allocation-for-mosti-approved-minister-says-govts-covid-19-vaccine-deal-onl/1929671
Stock
2020-12-08 08:50 | Report Abuse
“The government’s deal is only with Pfizer and Covax, and does not go through any third party or middleman,” he added.
https://www.malaymail.com/news/malaysia/2020/12/07/allocation-for-mosti-approved-minister-says-govts-covid-19-vaccine-deal-onl/1929671
Stock
2020-12-08 08:50 | Report Abuse
“The government’s deal is only with Pfizer and Covax, and does not go through any third party or middleman,” he added.
https://www.malaymail.com/news/malaysia/2020/12/07/allocation-for-mosti-approved-minister-says-govts-covid-19-vaccine-deal-onl/1929671
Stock
2020-12-08 08:49 | Report Abuse
“The government’s deal is only with Pfizer and Covax, and does not go through any third party or middleman,” he added.
https://www.malaymail.com/news/malaysia/2020/12/07/allocation-for-mosti-approved-minister-says-govts-covid-19-vaccine-deal-onl/1929671
Stock
2020-12-08 08:49 | Report Abuse
“The government’s deal is only with Pfizer and Covax, and does not go through any third party or middleman,” he added.
https://www.malaymail.com/news/malaysia/2020/12/07/allocation-for-mosti-approved-minister-says-govts-covid-19-vaccine-deal-onl/1929671
Stock
2020-12-08 08:47 | Report Abuse
“The government’s deal is only with Pfizer and Covax, and does not go through any third party or middleman,” he added.
https://www.malaymail.com/news/malaysia/2020/12/07/allocation-for-mosti-approved-minister-says-govts-covid-19-vaccine-deal-onl/1929671
Stock
2020-12-08 08:43 | Report Abuse
MyEG will be the sole distributor of the vaccine in Malaysia upon successful completion of the phase three trials, it said in a statement.
PETALING JAYA: My E.G. Services Bhd has entered into a memorandum of understanding (MoU) with Anhui Zhifei Longcom Biopharmaceutical Co Ltd to conduct phase three clinical trials and subsequent commercialisation of its Covid-19 vaccine in Malaysia.
MyEG will be the sole distributor of the vaccine in Malaysia upon successful completion of the phase three trials, it said in a statement.
Under the terms of the contract, the companies will strive to achieve compliance to halal status requirements to secure halal certification from the Department of Islamic Development Malaysia and ensure increased acceptance from the global Muslim population.
Zhifei is a subsidiary of Chongqing Zhifei Biological Products Co Ltd which is listed on the Shenzhen Stock Exchange and has been engaged in the biological products industry since 2002, particularly the production of vaccines for human use.
It is presently one of five Chinese companies conducting phase three clinical trials of the Covid-19 vaccine in various parts of the world.
The MoU is valid for three years from the date of signing and may be further extended upon mutual agreement.
The contract is not expected to have any material effect on the net asset per share and gearing of the company for financial year 2020 (FY20) but is expected to contribute positively in FY21 upon successful completion of the phase three trials and commercialisation of the vaccine.
Stock
2020-12-08 08:43 | Report Abuse
MyEG will be the sole distributor of the vaccine in Malaysia upon successful completion of the phase three trials, it said in a statement.
PETALING JAYA: My E.G. Services Bhd has entered into a memorandum of understanding (MoU) with Anhui Zhifei Longcom Biopharmaceutical Co Ltd to conduct phase three clinical trials and subsequent commercialisation of its Covid-19 vaccine in Malaysia.
MyEG will be the sole distributor of the vaccine in Malaysia upon successful completion of the phase three trials, it said in a statement.
Under the terms of the contract, the companies will strive to achieve compliance to halal status requirements to secure halal certification from the Department of Islamic Development Malaysia and ensure increased acceptance from the global Muslim population.
Zhifei is a subsidiary of Chongqing Zhifei Biological Products Co Ltd which is listed on the Shenzhen Stock Exchange and has been engaged in the biological products industry since 2002, particularly the production of vaccines for human use.
It is presently one of five Chinese companies conducting phase three clinical trials of the Covid-19 vaccine in various parts of the world.
The MoU is valid for three years from the date of signing and may be further extended upon mutual agreement.
The contract is not expected to have any material effect on the net asset per share and gearing of the company for financial year 2020 (FY20) but is expected to contribute positively in FY21 upon successful completion of the phase three trials and commercialisation of the vaccine.
Stock
2020-12-08 08:43 | Report Abuse
MyEG will be the sole distributor of the vaccine in Malaysia upon successful completion of the phase three trials, it said in a statement.
PETALING JAYA: My E.G. Services Bhd has entered into a memorandum of understanding (MoU) with Anhui Zhifei Longcom Biopharmaceutical Co Ltd to conduct phase three clinical trials and subsequent commercialisation of its Covid-19 vaccine in Malaysia.
MyEG will be the sole distributor of the vaccine in Malaysia upon successful completion of the phase three trials, it said in a statement.
Under the terms of the contract, the companies will strive to achieve compliance to halal status requirements to secure halal certification from the Department of Islamic Development Malaysia and ensure increased acceptance from the global Muslim population.
Zhifei is a subsidiary of Chongqing Zhifei Biological Products Co Ltd which is listed on the Shenzhen Stock Exchange and has been engaged in the biological products industry since 2002, particularly the production of vaccines for human use.
It is presently one of five Chinese companies conducting phase three clinical trials of the Covid-19 vaccine in various parts of the world.
The MoU is valid for three years from the date of signing and may be further extended upon mutual agreement.
The contract is not expected to have any material effect on the net asset per share and gearing of the company for financial year 2020 (FY20) but is expected to contribute positively in FY21 upon successful completion of the phase three trials and commercialisation of the vaccine.
Stock
2020-12-08 08:42 | Report Abuse
MyEG will be the sole distributor of the vaccine in Malaysia upon successful completion of the phase three trials, it said in a statement.
PETALING JAYA: My E.G. Services Bhd has entered into a memorandum of understanding (MoU) with Anhui Zhifei Longcom Biopharmaceutical Co Ltd to conduct phase three clinical trials and subsequent commercialisation of its Covid-19 vaccine in Malaysia.
MyEG will be the sole distributor of the vaccine in Malaysia upon successful completion of the phase three trials, it said in a statement.
Under the terms of the contract, the companies will strive to achieve compliance to halal status requirements to secure halal certification from the Department of Islamic Development Malaysia and ensure increased acceptance from the global Muslim population.
Zhifei is a subsidiary of Chongqing Zhifei Biological Products Co Ltd which is listed on the Shenzhen Stock Exchange and has been engaged in the biological products industry since 2002, particularly the production of vaccines for human use.
It is presently one of five Chinese companies conducting phase three clinical trials of the Covid-19 vaccine in various parts of the world.
The MoU is valid for three years from the date of signing and may be further extended upon mutual agreement.
The contract is not expected to have any material effect on the net asset per share and gearing of the company for financial year 2020 (FY20) but is expected to contribute positively in FY21 upon successful completion of the phase three trials and commercialisation of the vaccine.
Stock
2020-12-08 08:42 | Report Abuse
MyEG will be the sole distributor of the vaccine in Malaysia upon successful completion of the phase three trials, it said in a statement.
PETALING JAYA: My E.G. Services Bhd has entered into a memorandum of understanding (MoU) with Anhui Zhifei Longcom Biopharmaceutical Co Ltd to conduct phase three clinical trials and subsequent commercialisation of its Covid-19 vaccine in Malaysia.
MyEG will be the sole distributor of the vaccine in Malaysia upon successful completion of the phase three trials, it said in a statement.
Under the terms of the contract, the companies will strive to achieve compliance to halal status requirements to secure halal certification from the Department of Islamic Development Malaysia and ensure increased acceptance from the global Muslim population.
Zhifei is a subsidiary of Chongqing Zhifei Biological Products Co Ltd which is listed on the Shenzhen Stock Exchange and has been engaged in the biological products industry since 2002, particularly the production of vaccines for human use.
It is presently one of five Chinese companies conducting phase three clinical trials of the Covid-19 vaccine in various parts of the world.
The MoU is valid for three years from the date of signing and may be further extended upon mutual agreement.
The contract is not expected to have any material effect on the net asset per share and gearing of the company for financial year 2020 (FY20) but is expected to contribute positively in FY21 upon successful completion of the phase three trials and commercialisation of the vaccine.
Stock
2020-12-08 08:41 | Report Abuse
MyEG will be the sole distributor of the vaccine in Malaysia upon successful completion of the phase three trials, it said in a statement.
PETALING JAYA: My E.G. Services Bhd has entered into a memorandum of understanding (MoU) with Anhui Zhifei Longcom Biopharmaceutical Co Ltd to conduct phase three clinical trials and subsequent commercialisation of its Covid-19 vaccine in Malaysia.
MyEG will be the sole distributor of the vaccine in Malaysia upon successful completion of the phase three trials, it said in a statement.
Under the terms of the contract, the companies will strive to achieve compliance to halal status requirements to secure halal certification from the Department of Islamic Development Malaysia and ensure increased acceptance from the global Muslim population.
Zhifei is a subsidiary of Chongqing Zhifei Biological Products Co Ltd which is listed on the Shenzhen Stock Exchange and has been engaged in the biological products industry since 2002, particularly the production of vaccines for human use.
It is presently one of five Chinese companies conducting phase three clinical trials of the Covid-19 vaccine in various parts of the world.
The MoU is valid for three years from the date of signing and may be further extended upon mutual agreement.
The contract is not expected to have any material effect on the net asset per share and gearing of the company for financial year 2020 (FY20) but is expected to contribute positively in FY21 upon successful completion of the phase three trials and commercialisation of the vaccine.
Stock
2020-12-07 22:08 | Report Abuse
frontier ... haha. Nothing news from Dsonic
Stock
2020-12-07 22:05 | Report Abuse
Rakuten recommends these stocks for 2021 - http://www.theedgemarkets.com/article/rakuten-recommends-these-stocks-2021 (Share from StockHunter)
Stock
Stock
2020-12-07 22:02 | Report Abuse
https://youtu.be/43y184A7vRQ
第十一分钟开始
Stock
2020-12-07 22:02 | Report Abuse
https://youtu.be/43y184A7vRQ
第十一分钟开始
Stock
Stock
Stock
Stock
Stock
Stock
Stock
Stock
Stock
Stock
Stock
Stock
Stock
Stock
Stock
Stock
Stock
2020-12-07 12:06 | Report Abuse
Congratulations to MYEG’s investors. Price up over 12%
Stock
Stock
2020-12-07 10:56 | Report Abuse
KUALA LUMPUR (Dec 7): MY E.G. Services Bhd (MYEG) announced today that it has entered into a cooperation with Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (Zhifei) to obtain Malaysian Halal certification for the Chinese biopharma company’s COVID-19 vaccine and to exclusively distribute the vaccine in Malaysia for a 3-year period.
In a statement today, MYEG said the two companies have signed a Memorandum of Understanding, agreeing to cooperate in conducting Phase 3 clinical trials of Zhifei’s vaccine in Malaysia and in achieving compliance to Halal status requirements to secure Halal certification from the Department of Islamic Development Malaysia (JAKIM).
MYEG said the commencement of Phase 3 trial will make Zhifei’s vaccine one of the first to undergo this final stage trial in Malaysia under the purview of the Ministry of Health.
Zhifei is a subsidiary of Chongqing Zhifei Biological Products Co., Ltd., which is listed on the Shenzhen Stock Exchange and has been engaged in the biological products industry since 2002, mainly the production of vaccines for human use. Zhifei is presently one of five Chinese companies conducting Phase 3 clinical trials of their COVID-19 vaccines in various parts of the world.
Upon successful completion of the Phase 3 trials, MYEG will be the sole distributor of the vaccine in Malaysia.
Since Nov 1, 2020, MYEG has been appointed by the Malaysian Ministry of Health to develop and operate the MySafeTravel digital health pass system to facilitate inbound travellers’ compliance to mandatory COVID-19 testing and quarantine requirements.
In addition, MYEG also operates a one-stop portal for the COVID-19 screening of workers in the country, which includes a data sharing collaboration with the Department of Labour of Peninsular Malaysia.
MYEG was last traded at RM1.81, valuing it at RM6.61 billion.
Stock
2020-12-07 10:55 | Report Abuse
KUALA LUMPUR (Dec 7): MY E.G. Services Bhd (MYEG) announced today that it has entered into a cooperation with Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (Zhifei) to obtain Malaysian Halal certification for the Chinese biopharma company’s COVID-19 vaccine and to exclusively distribute the vaccine in Malaysia for a 3-year period.
In a statement today, MYEG said the two companies have signed a Memorandum of Understanding, agreeing to cooperate in conducting Phase 3 clinical trials of Zhifei’s vaccine in Malaysia and in achieving compliance to Halal status requirements to secure Halal certification from the Department of Islamic Development Malaysia (JAKIM).
MYEG said the commencement of Phase 3 trial will make Zhifei’s vaccine one of the first to undergo this final stage trial in Malaysia under the purview of the Ministry of Health.
Zhifei is a subsidiary of Chongqing Zhifei Biological Products Co., Ltd., which is listed on the Shenzhen Stock Exchange and has been engaged in the biological products industry since 2002, mainly the production of vaccines for human use. Zhifei is presently one of five Chinese companies conducting Phase 3 clinical trials of their COVID-19 vaccines in various parts of the world.
Upon successful completion of the Phase 3 trials, MYEG will be the sole distributor of the vaccine in Malaysia.
Since Nov 1, 2020, MYEG has been appointed by the Malaysian Ministry of Health to develop and operate the MySafeTravel digital health pass system to facilitate inbound travellers’ compliance to mandatory COVID-19 testing and quarantine requirements.
In addition, MYEG also operates a one-stop portal for the COVID-19 screening of workers in the country, which includes a data sharing collaboration with the Department of Labour of Peninsular Malaysia.
MYEG was last traded at RM1.81, valuing it at RM6.61 billion.
Stock
2020-12-07 10:55 | Report Abuse
KUALA LUMPUR (Dec 7): MY E.G. Services Bhd (MYEG) announced today that it has entered into a cooperation with Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (Zhifei) to obtain Malaysian Halal certification for the Chinese biopharma company’s COVID-19 vaccine and to exclusively distribute the vaccine in Malaysia for a 3-year period.
In a statement today, MYEG said the two companies have signed a Memorandum of Understanding, agreeing to cooperate in conducting Phase 3 clinical trials of Zhifei’s vaccine in Malaysia and in achieving compliance to Halal status requirements to secure Halal certification from the Department of Islamic Development Malaysia (JAKIM).
MYEG said the commencement of Phase 3 trial will make Zhifei’s vaccine one of the first to undergo this final stage trial in Malaysia under the purview of the Ministry of Health.
Zhifei is a subsidiary of Chongqing Zhifei Biological Products Co., Ltd., which is listed on the Shenzhen Stock Exchange and has been engaged in the biological products industry since 2002, mainly the production of vaccines for human use. Zhifei is presently one of five Chinese companies conducting Phase 3 clinical trials of their COVID-19 vaccines in various parts of the world.
Upon successful completion of the Phase 3 trials, MYEG will be the sole distributor of the vaccine in Malaysia.
Since Nov 1, 2020, MYEG has been appointed by the Malaysian Ministry of Health to develop and operate the MySafeTravel digital health pass system to facilitate inbound travellers’ compliance to mandatory COVID-19 testing and quarantine requirements.
In addition, MYEG also operates a one-stop portal for the COVID-19 screening of workers in the country, which includes a data sharing collaboration with the Department of Labour of Peninsular Malaysia.
MYEG was last traded at RM1.81, valuing it at RM6.61 billion.
Stock
2020-12-07 10:54 | Report Abuse
KUALA LUMPUR (Dec 7): MY E.G. Services Bhd (MYEG) announced today that it has entered into a cooperation with Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (Zhifei) to obtain Malaysian Halal certification for the Chinese biopharma company’s COVID-19 vaccine and to exclusively distribute the vaccine in Malaysia for a 3-year period.
In a statement today, MYEG said the two companies have signed a Memorandum of Understanding, agreeing to cooperate in conducting Phase 3 clinical trials of Zhifei’s vaccine in Malaysia and in achieving compliance to Halal status requirements to secure Halal certification from the Department of Islamic Development Malaysia (JAKIM).
MYEG said the commencement of Phase 3 trial will make Zhifei’s vaccine one of the first to undergo this final stage trial in Malaysia under the purview of the Ministry of Health.
Zhifei is a subsidiary of Chongqing Zhifei Biological Products Co., Ltd., which is listed on the Shenzhen Stock Exchange and has been engaged in the biological products industry since 2002, mainly the production of vaccines for human use. Zhifei is presently one of five Chinese companies conducting Phase 3 clinical trials of their COVID-19 vaccines in various parts of the world.
Upon successful completion of the Phase 3 trials, MYEG will be the sole distributor of the vaccine in Malaysia.
Since Nov 1, 2020, MYEG has been appointed by the Malaysian Ministry of Health to develop and operate the MySafeTravel digital health pass system to facilitate inbound travellers’ compliance to mandatory COVID-19 testing and quarantine requirements.
In addition, MYEG also operates a one-stop portal for the COVID-19 screening of workers in the country, which includes a data sharing collaboration with the Department of Labour of Peninsular Malaysia.
MYEG was last traded at RM1.81, valuing it at RM6.61 billion.
Stock
2020-12-07 10:54 | Report Abuse
KUALA LUMPUR (Dec 7): MY E.G. Services Bhd (MYEG) announced today that it has entered into a cooperation with Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (Zhifei) to obtain Malaysian Halal certification for the Chinese biopharma company’s COVID-19 vaccine and to exclusively distribute the vaccine in Malaysia for a 3-year period.
In a statement today, MYEG said the two companies have signed a Memorandum of Understanding, agreeing to cooperate in conducting Phase 3 clinical trials of Zhifei’s vaccine in Malaysia and in achieving compliance to Halal status requirements to secure Halal certification from the Department of Islamic Development Malaysia (JAKIM).
MYEG said the commencement of Phase 3 trial will make Zhifei’s vaccine one of the first to undergo this final stage trial in Malaysia under the purview of the Ministry of Health.
Zhifei is a subsidiary of Chongqing Zhifei Biological Products Co., Ltd., which is listed on the Shenzhen Stock Exchange and has been engaged in the biological products industry since 2002, mainly the production of vaccines for human use. Zhifei is presently one of five Chinese companies conducting Phase 3 clinical trials of their COVID-19 vaccines in various parts of the world.
Upon successful completion of the Phase 3 trials, MYEG will be the sole distributor of the vaccine in Malaysia.
Since Nov 1, 2020, MYEG has been appointed by the Malaysian Ministry of Health to develop and operate the MySafeTravel digital health pass system to facilitate inbound travellers’ compliance to mandatory COVID-19 testing and quarantine requirements.
In addition, MYEG also operates a one-stop portal for the COVID-19 screening of workers in the country, which includes a data sharing collaboration with the Department of Labour of Peninsular Malaysia.
MYEG was last traded at RM1.81, valuing it at RM6.61 billion.
Stock
2020-12-07 10:53 | Report Abuse
KUALA LUMPUR (Dec 7): MY E.G. Services Bhd (MYEG) announced today that it has entered into a cooperation with Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (Zhifei) to obtain Malaysian Halal certification for the Chinese biopharma company’s COVID-19 vaccine and to exclusively distribute the vaccine in Malaysia for a 3-year period.
In a statement today, MYEG said the two companies have signed a Memorandum of Understanding, agreeing to cooperate in conducting Phase 3 clinical trials of Zhifei’s vaccine in Malaysia and in achieving compliance to Halal status requirements to secure Halal certification from the Department of Islamic Development Malaysia (JAKIM).
MYEG said the commencement of Phase 3 trial will make Zhifei’s vaccine one of the first to undergo this final stage trial in Malaysia under the purview of the Ministry of Health.
Zhifei is a subsidiary of Chongqing Zhifei Biological Products Co., Ltd., which is listed on the Shenzhen Stock Exchange and has been engaged in the biological products industry since 2002, mainly the production of vaccines for human use. Zhifei is presently one of five Chinese companies conducting Phase 3 clinical trials of their COVID-19 vaccines in various parts of the world.
Upon successful completion of the Phase 3 trials, MYEG will be the sole distributor of the vaccine in Malaysia.
Since Nov 1, 2020, MYEG has been appointed by the Malaysian Ministry of Health to develop and operate the MySafeTravel digital health pass system to facilitate inbound travellers’ compliance to mandatory COVID-19 testing and quarantine requirements.
In addition, MYEG also operates a one-stop portal for the COVID-19 screening of workers in the country, which includes a data sharing collaboration with the Department of Labour of Peninsular Malaysia.
MYEG was last traded at RM1.81, valuing it at RM6.61 billion.
Stock: [IRIS]: IRIS CORPORATION BHD
2020-12-08 13:27 | Report Abuse
Hot Stock - MyEG continues to climb after emerging as potential proxy for Covid-19 vaccine play - http://www.theedgemarkets.com/article/myeg-continues-climb-after-emerging-potential-proxy-covid19-vaccine-play (Share from StockHunter)